A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese

Journal of Biomedical Science

Volumn 10, Issue 4, 2003, Pages 430-435

  Suzuki, Kazuhiro ^a   Matsui, Hiroshi ^a   Ohtake, Nobuaki ^a   Nakata, Seiji ^a   Takei, Tomoyuki ^a   Nakazato, Haruki ^a   Okugi, Hironobu ^a   Koike, Hidekazu ^a   Ono, Yoshihiro ^a   Ito, Kazuto ^a   Kurokawa, Kohei ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Codon 72; p53; Prostate cancer

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILY HISTORY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; METASTASIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CODON; DISEASE PROGRESSION; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 10744220221     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000071162     Document Type: Article

References (24)

1. Brothman AR. Cytogenetics and molecular genetics of cancer of the prostate. Am J Med Genet 115:150-156;2002.
2. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence? J Natl Cancer Inst 85:1554-1557;1993.
3. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. p53 abnormalities in primary prostate cancer: Single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst 89:66-71;1997.
4. Hardy GH. Mendelian properties in a mixed population. Science 28:49-50;1908.
5. Harris CC. p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981;1993.
6. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 49:263-266;2001.
7. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453-456;1991.
8. Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu L-L, Lynch TJ, Wain JC, Su L, Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61:8718-8722;2001.
9. Makni H, Franco EL, Kaiano J, Villa LL, Labresque S, Dudley R, Storey A, Matlashewski G. p53 polymorphism in codon 72 and risk of human papillomavirus-associated cervical cancer: Effect of inter-laboratory variation. Int J Cancer 87:528-533;2000.
10. Malkin D, Li FP, Fraumeni JFJr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238;1990.
11. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Julug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47-54;2000.
12. Marx J. How p53 suppresses cell growth. Science 262:1644-1645;1993.
13. Nakano Y, Naoe T, Kiyoi H, Kunishima S, Minami S, Miyawaki S, Asou N, Kuriyama K, Saito H, Ohno R. Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. Leuk Res 24:349-352;2000.
14. Ngan HY, Liu VW, Liu SS, Cheng DK, Ng TY, Wong LC. Homozygous arginine at codon 72 of p53 has no prognostic significance in cervical cancer. Tumor Biol 21:135-138;2000.
15. Ohtake N, Hatori M, Yamanaka H, Nakata S, Sada M, Tsuji T. Familial prostate cancer in Japan. Int J Urol 5:138-145;1998.
16. Ohtake N, Nakata S, Sato J, Koya A, Saruki K, Kurihara J, Tsuji H, Imai K, Yamanaka H, Suzuki K, Tari K. Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines. Tohoku J Exp Med 184:21-28;1998.
17. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 20:22-45;1999.
18. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229-234;1998.
19. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variations of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100;1999.
20. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, Tsai CH. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112:116-119;2002.
21. Wang Y-C, Chen C-Y, Chen S-K, Chang Y-Y, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: Association with lung cancer susceptibility and prognosis. Clin Cancer Res 5:129-134;1999.
22. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 35:226-230;1999.
23. Wu W-J, Kakehi Y, Habuchi T, Kinoshita H, Ogawa O, Terachi T, Huang C-H, Chiang C-P, Yoshida O. Allelic frequency of p53 gene codon 72 polymorphism in urological cancers. Jpn J Cancer Res 86:730-736;1995.
24. Zang W, Hu G, Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogeneous leukemia. Gene 117:271-275;1992.